Zyversa Therapeutics, INC

ZyVersa Therapeutics, Inc. announced its common stock has ceased trading on the OTCQB Venture Market and commenced trading on the OTC Pink Limited Market, effective July 16, 2026.

ZyVersa Therapeutics is implementing cost-cutting measures and exploring strategic options, including potential divestitures and headcount reductions, as it seeks to raise capital and ensure continued operations.

ZyVersa Therapeutics, Inc. has raised $1 million through a private placement of convertible promissory notes and common stock purchase warrants to accredited investors for working capital.

Robert G. Finizio has resigned from ZyVersa Therapeutics' Board of Directors, effective immediately, citing personal reasons.

ZyVersa Therapeutics reported a significant increase in net losses for Q3 2025, primarily due to an $18.6 million R&D impairment, and indicated an urgent need for additional financing to sustain operations.

Dr. Pablo Guzman has resigned from his roles as Chief Medical Officer and Senior Vice President of Medical Affairs at ZyVersa Therapeutics, Inc., effective October 10, 2025.

ZyVersa Therapeutics reports a net loss of $1.8 million for Q1 2026, with significant cash burn and ongoing need for financing.

ZyVersa Therapeutics reported a significant net loss and an $18.6 million impairment charge, raising substantial doubt about its ability to continue as a going concern following its Nasdaq delisting.

ZyVersa Therapeutics reports significant losses and a going concern warning, with its common stock delisted from Nasdaq and now trading on OTCQB.

ZyVersa Therapeutics reports a net loss of $2.3 million for Q1 2025, with ongoing focus on developing its lead drug candidates VAR 200 and IC 100.

ZyVersa Therapeutics reported its Q3 2024 financial results, showing a net loss and ongoing efforts to secure additional funding.

ZyVersa Therapeutics reported a net loss of $5.6 million for the first half of 2024 and highlighted its need for additional financing to continue operations.

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, reported a significant net loss of $25.0 million in 2025, including an $18.6 million impairment charge, and was delisted from Nasdaq, raising substantial doubt about its going concern ability.

ZyVersa Therapeutics details its financial results for the year ended December 31, 2024, and outlines its strategic priorities for advancing its renal and inflammatory disease drug candidates.

ZyVersa Therapeutics has filed an amendment to its 2023 annual report to clarify existing language and update the number of outstanding shares, while also addressing identified material weaknesses in internal controls.

ZyVersa Therapeutics' 10-K filing provides a detailed overview of its capital structure, including common and preferred stock, warrants, and anti-takeover provisions.

ZyVersa Therapeutics, Inc.'s Chief Commercial Officer, Karen A. Cashmere, was granted 48,100 stock options with an exercise price of $0.59, vesting over three years, though the Form 4 filing was delayed due to an administrative oversight.

ZyVersa Therapeutics, Inc. Director Gregory Gene Freitag was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.

ZyVersa Therapeutics, Inc. CEO Stephen C. Glover was granted 136,900 stock options with an exercise price of $0.59, vesting over three years.

ZyVersa Therapeutics Director Robert G. Finizio was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.

Peter Wolfe, Chief Financial Officer of ZyVersa Therapeutics, Inc., was granted 60,100 stock options with an exercise price of $0.59 per share, vesting over three years.

ZyVersa Therapeutics, Inc. has granted its Chief Medical Officer, Pablo A. Guzman, 48,900 stock options with an exercise price of $0.59, vesting over three years.

Zyversa Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

ZyVersa Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify its accounting firm, and approve amendments to its equity incentive plan and warrant issuances.

ZyVersa Therapeutics is seeking stockholder approval to issue up to 1,637,000 shares upon the exercise of certain warrants, aiming to raise approximately $3.4 million.

Zyversa Therapeutics, Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

ZyVersa Therapeutics is holding its annual meeting to vote on key proposals including director election, auditor ratification, an equity incentive plan amendment, and approval for the issuance of common stock upon warrant exercises.

ZyVersa Therapeutics is seeking shareholder approval for a potential reverse stock split to maintain Nasdaq listing and attract investors amid a challenging biotech environment.

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, is raising up to $14.1 million through equity agreements and warrant exercises while navigating a Nasdaq delisting and significant going concern doubts.

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, is registering shares for resale to raise capital following its delisting from Nasdaq and amidst significant financial challenges, including substantial doubt about its ability to continue as a going concern.

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has entered into an equity purchase agreement to raise up to $10 million, while simultaneously facing substantial doubt about its ability to continue as a going concern and ongoing Nasdaq listing compliance challenges.

Armistice Capital, LLC reports a decreased ownership stake in ZyVersa Therapeutics, Inc., falling below the 5% threshold.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, revealing a 9.99% passive ownership stake in ZyVersa Therapeutics, Inc.